ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Oncology"

  • Abstract Number: 1058 • ACR Convergence 2023

    Resolution of Immune Checkpoint Inhibitors-Induced Inflammatory Arthritis While Maintaining Active Treatment with Checkpoint Inhibitors

    Alexandra Ladouceur1, Thomas Barnetche2, Sorilla Mary-Prey3, Caroline Dutriaux4, Emilie Gerard3, Anne Pham-Ledard3, Marie Beylot-Barry3, Maeva Zysman3, Rémi Veillon3, Charlotte Domblides5, Amaury Daste5, Marine Gross-Goupil5, Baptiste Sionneau5, Félix Lefort5, Mathieu Larroquette5, Christophe Richez6, Marie-Elise Truchetet2, Thierry Schaeverbebke7 and Marie Kostine2, 1Department of Rheumatology of McGill University and CHU-Bordeaux, Montréal, QC, Canada, 2Bordeaux University Hospital, Bordeaux, France, 3Department of Dermatology, Bordeaux University Hospital, Bordeaux, France, 4CHU-Bordeaux, Bordeaux, France, 5Department of Medical Oncology, Bordeaux University Hospital, Bordeaux, France, 6Université de Bordeaux, Bordeaux, France, 7University Hospital of Bordeaux, Bordeaux, France

    Background/Purpose: Immune checkpoint inhibitors (ICI) are a revolutionary treatment that boost a patient's own immune system to fight cancer. However, activation of the immune system…
  • Abstract Number: 1074 • ACR Convergence 2023

    Baseline Clinical Features, but Not Shared Epitope or HLA B27, Predict Severe Outcomes for Immune Checkpoint Inhibitor-induced Inflammatory Arthritis

    Laura Cappelli1, omer Kamal2, Michelle Jones3, Clifton Bingham4 and Ami Shah5, 1Johns Hopkins School of Medicine, Baltimore, MD, 2St. Agnes Hospital, Baltimore, MD, 3Johns Hopkins University School of Medicine, Baltimore, MD, 4Johns Hopkins University, Baltimore, MD, 5Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Ellicott City, MD

    Background/Purpose: Immune checkpoint inhibitors (ICI) can cause inflammatory arthritis (IA) of varying severity. Many patients with ICI-IA require immunosuppression beyond corticosteroids, but there is no…
  • Abstract Number: 1678 • ACR Convergence 2023

    Comparative Safety of Biologic and Targeted Synthetic Disease Modifying Anti-Rheumatic Drugs for Cancer in Rheumatoid Arthritis

    Xavier Sendaydiego1, Laura Gold2, Jean liew3, K Wysham4, Maureen Dubreuil5, James Andrews1, Pankti Reid6, David Liew7, Radjiv Goulabchand8, Abha Singh9, Grant Hughes1, Mathilde Pioro1, Jeffrey Sparks10, Jeffrey Jarvik2, Siddharth Singh9 and Namrata Singh11, 1University of Washington, Seattle, WA, 2Department of Radiology and University of Washington Clinical Learning, Evidence, and Research (CLEAR) Center for Musculoskeletal Disorders, Seattle, WA, 3Boston University, Boston, MA, 4VA Puget Sound/University of Washington, Seattle, WA, 5Department of Rheumatology, Boston University School of Medicine, Milton, MA, 6University of Chicago Medical Center, Chicago, IL, 7Austin Health, Heidelberg, Australia, 8St. Eloi Hospital, Department of Internal Medicine and Multi-Organic Diseases, Montpellier, France, 9University of California San Diego, San Diego, CA, 10Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, 11University of Washington, Bellevue, WA

    Background/Purpose: In the ORAL Surveillance trial, cancer risk was higher among patients with rheumatoid arthritis (RA) on tofacitinib, a Janus kinase inhibitor (JAKi), compared to…
  • Abstract Number: 2015 • ACR Convergence 2023

    Synergistic Effect Between Denosumab and Immune Checkpoint Inhibitors : A Retrospective Study of 268 Patients with Bone Metastases

    Emmanuel Massy1, Etienne Mabrut1, Sabine Mainbourg2 and Cyrille Confavreux1, 1Centre Expert des Métastases Osseuses (CEMOS) - Service de Rhumatologie, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Université de Lyon, INSERM UMR 1033-LYOS, Lyon, France, 2Service de médecine interne et vasculaire, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, F-69495 Pierre-Bénite, Laboratoire de Biométrie et Biologie Evolutive, Université Lyon 1; CNRS, UMR 5558, 69622 Villeurbanne, Lyon, France

    Background/Purpose: Bone is the third site of metastasis. Bone metastases are associated with poorer survival of patients and impaired quality of life with the occurrence…
  • Abstract Number: 2127 • ACR Convergence 2023

    Associations Between Rheumatoid Arthritis, Frailty Status and Mortality in Older Adults with Bladder Cancer

    Maya Swaminathan1, Sarah Holt2, John Gore2, Yaw Nyame2, Jonathan Wright2, George Schade2, Ami Shah3, Jeffrey Sparks4, Una Makris5, Petros Grivas6, Maria Suarez-Almazor7, Sarah Psutka2 and Namrata Singh8, 1University of Washington, Seattle, WA, 2Department of Urology, University of Washington, Seattle, WA, 3Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Ellicott City, MD, 4Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, 5UT Southwestern Medical Center and Dallas VA, Dallas, TX, 6Division of Medical Oncology, Dept. of Medicine, UW; Clinical Research Division; Fred Hutchinson Cancer Center, Seattle, WA, 7MD Anderson Cancer Center, Houston, TX, 8University of Washington, Bellevue, WA

    Background/Purpose: Rheumatoid arthritis (RA) is associated with an increased risk of developing certain cancers, including bladder cancer (Beydon et al. 20231). However, few studies have…
  • Abstract Number: 2139 • ACR Convergence 2023

    Associations of Adipocytokines with Cancer Incidence in a Prospective Rheumatoid Arthritis Cohort

    Namrata Singh1, Aaron Baraff2, K Wysham3, Punyasha Roul4, Grant Cannon5, Brian Sauer6, Geoffrey Thiele4, Bryant England4, Ted R Mikuls7 and Joshua Baker8, 1University of Washington, Bellevue, WA, 2VA Puget Sound Seattle, Seattle, WA, 3VA Puget Sound/University of Washington, Seattle, WA, 4University of Nebraska Medical Center, Omaha, NE, 5University of Utah and Salt Lake City VA, Salt Lake City, UT, 6Salt Lake City VA/University of Utah, Salt Lake City, UT, 7Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE, 8University of Pennsylvania, Philadelphia, PA

    Background/Purpose: A prior study suggested a higher risk of cancer mortality in patients with rheumatoid arthritis (RA) with higher levels of circulating leptin, an adipocytokine…
  • Abstract Number: 2138 • 2019 ACR/ARP Annual Meeting

    Rheumatic Immune-related Adverse Effects from Checkpoint Inhibitor Immunotherapy in Patients with Solid Tumors in a Latin American Population

    Alain Sánchez-Rodríguez1, Elina Alexandra Rodriguez-Melendez 2, Alonso Turrent-Carriles 3, Paola Bermúdez-Bermejo 3, josé Fabián Martínez-Herrera 2 and Raquel Gerson-Cwilich 2, 1Hospital General de Mexico, Mexico City, Distrito Federal, Mexico, 2ABC Medical Center, Oncology Department, Ciudad de Mexico, Distrito Federal, Mexico, 3ABC Medical Center, Rheumatology Department, Ciudad de Mexico, Distrito Federal, Mexico

    Background/Purpose: Cancer immunotherapy is a newly-approved approach in the management of advanced malignancies. Immune checkpoint inhibitors (ICIs) are the most commonly used type of cancer…
  • Abstract Number: 364 • 2018 ACR/ARHP Annual Meeting

    Elevated sCD40L As a Predictive Biomarker of Immune-Related Adverse Events in Patients Receiving Immune Checkpoint Inhibitors

    Nicholas Meti1, Khashayar Esfahani1,2, Ines Colmegna1,3, Marvin J. Fritzler4, Nathalie A. Johnson1,5, Ciriaco Piccirillo1,6, Wilson H. Miller Jr.1,2 and Marie Hudson1,7, 1Department of Medicine, McGill University, Montreal, QC, Canada, 2Department of Oncology, McGill University, Jewish General Hospital, Rossy Cancer Network, Montreal, QC, Canada, 3Division of Rheumatology, McGill University Health Centre, Montreal, QC, Canada, 4Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, 5Division of Hematology, Jewish General Hospital, Montreal, QC, Canada, 6Department of Microbiology & Immunology, McGill University, Montreal, QC, Canada, 7Division of Rheumatology, Jewish General Hospital, Montreal, QC, Canada

    Background/Purpose: The clinical use of immune checkpoint inhibitors (ICI) has led to outstanding clinical outcomes in previously refractory cancers, but ICI have also been associated…
  • Abstract Number: 1914 • 2018 ACR/ARHP Annual Meeting

    Rheumatic Syndromes Associated with Immune-Checkpoint Inhibitors: A Single-Center Cohort of 61 Patients

    Michael Richter1, Cynthia S. Crowson2, Lisa Kottschade3, Heidi Finnes3, Svetomir N. Markovic4 and Uma Thanarajasingam5, 1Internal Medicine, Mayo Clinic, Rochester, MN, 2Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, 3Oncology, Mayo Clinic, Rochester, MN, 4Department of Medicine and Oncology, Mayo Clinic, Rochester, MN, 5Department of Rheumatology, Mayo Clinic, Rochester, MN

    Background/Purpose: Rheumatologists are increasingly called upon to manage the autoimmune side effects of immune-checkpoint inhibitors (ICIs). However, these new entities are poorly understood and treatment…
  • Abstract Number: 1880 • 2017 ACR/ARHP Annual Meeting

    Cancer Immunotherapy in Patients with Preexisting Rheumatologic Disease: The Mayo Clinic Experience

    Michael Richter1, Olga Pinkston2, Lisa Kottschade3, Heidi Finnes3, Svetomir N. Markovic4 and Uma Thanarajasingam5, 1Internal Medicine, Mayo Clinic, Rochester, MN, 2Rheumatology, Mayo Clinic Florida, Jacksonville, FL, 3Oncology, Mayo Clinic, Rochester, MN, 4Department of Medicine and Oncology, Mayo Clinic, Rochester, MN, 5Division of Rheumatology, Mayo Clinic, Rochester, MN

    Background/Purpose: Immune checkpoint inhibitors have revolutionized the treatment of advanced malignancies. By blocking T-cell inhibition these drugs result in immune targeting of tumor cells and…
  • « Previous Page
  • 1
  • 2
  • 3
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology